Exploring serum biomarkers in Parkinson's disease and atypical Parkinsonian syndrome
NMR Based Metabolomic Study of Serum Biomarkers in Patients With Parkinson's Disease and Atypical Parkinsonian Syndrome
This study is trying to find specific blood markers that can help doctors tell the difference between Parkinson's disease and similar conditions to improve early diagnosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 180 (estimated) |
| Ages | 45 Years to 80 Years |
| Sex | All |
| Sponsor | Fujian Medical University Union Hospital Academic / other |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT06490926 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the metabolomic characteristics of patients with Parkinson's disease (PD) and atypical Parkinsonian syndrome (APS) using proton nuclear magnetic resonance spectroscopy. The focus is on identifying reliable biomarkers that can aid in the early diagnosis of these conditions, which are often confused in their initial stages. By analyzing serum samples, the study seeks to provide insights into the metabolic changes associated with PD and APS, potentially leading to improved diagnostic methods. The research addresses a critical need for early intervention strategies in neurodegenerative diseases.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 45 to 80 who have been diagnosed with multiple system atrophy or progressive supranuclear palsy.
Not a fit: Patients outside the age range of 45 to 80 or those without a diagnosis of multiple system atrophy or progressive supranuclear palsy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of reliable biomarkers for early diagnosis of Parkinson's disease and atypical Parkinsonian syndrome, improving patient outcomes.
How similar studies have performed: While there is ongoing research in the field of metabolomics for neurodegenerative diseases, this specific approach using proton nuclear magnetic resonance spectroscopy for PD and APS is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* 1\) MSA and PSP inclusion criteria
* Age range from 45 to 80 years old;
1. MSA inclusion criteria
* Age range from 45 to 80 years old;
* Meets the Chinese expert consensus on the diagnostic criteria for multiple system atrophy (2017) or the International Society for Parkinson\'s Disease and Movement Disorders (MDS) diagnostic criteria for multiple system atrophy (2022)
③ MSA subtype grouping: MSA is divided into MSA-P and MSA-C subtypes based on the severity of initial and/or motor symptoms, with Patients with Parkinson\'s syndrome as the main type are MSA-P, while patients with cerebellar syndrome as the main type are MSA-C.
(2) PSP inclusion criteria
* Age range from 45 to 80 years old;
② PSP patients who meet the diagnostic criteria for progressive supranuclear palsy in China (2016) or the diagnostic criteria for progressive supranuclear palsy in the International Society for Parkinson\'s Disease and Movement Disorders (MDS) (2017)
(3) Selection criteria for Parkinson\'s disease case group
* Age range from 45 to 80 years old;
* Patients with idiopathic Parkinson\'s disease who meet the diagnostic criteria of the International Committee on Motor Disorders (MDS) for Parkinson\'s disease (2015);
* Classification criteria for subtypes of Parkinson\'s disease:
1. Tremor predominant type: According to the MDS-UPDRS score, the ratio of average tremor score to average PIGD score is ≥ 1.15
2. PIGD type: According to the MDS-UPDRS score, the ratio of average tremor score to average PIGD score is ≤ 0.9
Exclusion Criteria:
* ① Hereditary Parkinson\'s syndrome, secondary Parkinson\'s syndrome.
* After deep brain stimulation (DBS) surgery.
* Have a history of malignant tumors.
Where this trial is running
Fuzhou, Fujian
- Fujian Medical University Union Hospital — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Study coordinator: Ying Chen associate chief physician, Master
- Email: 2320609050@qq.com
- Phone: 13365910067
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.